Mehmetoğlu Gürbüz Tuğba, Oral Ethem Nezih, Dağoğlu Sakin Rabia Nergiz, Karaman Şule, Durak Şermin, Aksoyer Sezgin Saadet Büşra, Keskin Metin, Çelik Faruk, Zeybek Ş Ümit
Aziz Sancar Institute of Experimental Medicine, Department of Molecular Medicine, Istanbul University, Topkapi, Gureba Hospital Street, Number: 69, 34093 Fatih/Istanbul, Turkey.
Institute of Oncology, Department of Radiation Oncology, Istanbul University, Istanbul, Turkey.
Indian J Clin Biochem. 2025 Apr;40(2):263-273. doi: 10.1007/s12291-023-01177-6. Epub 2024 Jan 18.
Radiotherapy (RT) which is a treatment regime for cancer patients may cause genetic instability and side effects. Etiological associations exist amongst autophagy-related gene (ATG) mutation and cancer. RT increases the rate of autophagy previously proven in vitro. The aforementioned background diverted us to conduct exon mutation analysis for ATG5, ATG12, and ATG9B genes of colorectal cancer patients who were receiving neoadjuvant RT. Peripheral blood DNA from different time points (before/middle/after RT) of the same patients was isolated and most tandem repeat-containing exons of ATG5, ATG12, and ATG9B were polymerase chain reaction-amplified and examined for mutations by Sanger sequencing. CA19-9/CEA (Tumor marker of colorectal cancer/Carcinoembryonic Antigen) serum levels were retrieved from the clinic. No exon variations detected for ATG5 and ATG12 genes. However, 4 patients (17.4%) showed frameshift mutation for ATG9B gene. Exon variation analysis of 2 (8.7%) patients resulted in GGG deletion at 8G mononucleotide tandem repeat region of ATG9B. Assigning patients as before RT and after RT, CA19-9 levels in ATG9B (Mutation) patients were higher compared to ATG9B (Wild Type) patients. ATG9B is highly likely to mutate during RT and ATG9B mutation correlates to higher CEA and CA19-9 levels and patients show poor prognosis.
The online version contains supplementary material available at 10.1007/s12291-023-01177-6.
放射疗法(RT)是癌症患者的一种治疗方案,可能会导致基因不稳定和副作用。自噬相关基因(ATG)突变与癌症之间存在病因学关联。放射疗法会提高此前在体外已得到证实的自噬速率。上述背景促使我们对接受新辅助放射疗法的结直肠癌患者的ATG5、ATG12和ATG9B基因进行外显子突变分析。分离同一患者不同时间点(放疗前/放疗中/放疗后)的外周血DNA,对ATG5、ATG12和ATG9B的大多数含串联重复序列的外显子进行聚合酶链反应扩增,并通过桑格测序检测突变情况。从临床记录中获取CA19-9/CEA(结直肠癌肿瘤标志物/癌胚抗原)血清水平。未检测到ATG5和ATG12基因的外显子变异。然而,4名患者(17.4%)的ATG9B基因出现移码突变。2名患者(8.7%)的外显子变异分析结果显示,ATG9B的8G单核苷酸串联重复区域发生GGG缺失。将患者分为放疗前和放疗后两组,ATG9B(突变)患者的CA19-9水平高于ATG9B(野生型)患者。ATG9B在放疗期间极有可能发生突变,且ATG9B突变与较高的CEA和CA19-9水平相关,患者预后较差。
在线版本包含可在10.1007/s12291-023-01177-6获取的补充材料。